Hypertension Flashcards
Beta-1 selective drugs (AMEBBA)
A- ATENOLOL
M- METOPROLOL
E- ESMOLOL
B- BETAXOLOL
B- BISOPROLOL
A- ACEBUTLOL
Beta 1 selective b- blocker with Nitric Oxide- dependent vasodilatation
Nebivolol
Non selective beta blockers and alph 1 blockers
(Leave Cardiac To Periphery Soon)
L- labetalol
C - Carvedilol
T- Timolol
P- Pindolol + Propranolol
S- Sotalol
CAPTOPRIL to remember key SE of ACE inhibitors (ACEi):
C – Cough (due to increased bradykinin)
A – Angioedema (rare but serious side effect)
P – Potassium retention (risk of hyperkalemia)
T – Teratogenic (contraindicated in pregnancy)
O – Orthostatic hypotension (especially with first doses)
P – Proteinuria (can reduce proteinuria in nephropathy)
R – Renal function monitoring (risk of acute kidney injury)
I – Increased creatinine (due to decreased GFR, needs monitoring)
L – Lowers blood pressure (main use in hypertension and heart failure)
Antihytn best in asthmatics
Low dose digoxin and CCB
Pillars in the management of HF
1.BB
2.ARNI
3.ACEI/ ARBS
4.SGLT2
5.Mineralocorticoid Receptor Antagonist
ARNI ( Sacubitril /Valsartan )
Salcubitril -
Neprilysing breaks down peptides but these peptides are useful in the excretion of sodium and water
Salcubitril inhibits Neprilysing to prevent the breakdown of peptides
NYHA class I
No symptoms and no limitation of ordinary physical activity
NYHA class II
No symptoms at rest but slight limitation of ordinary activity
NYHA class III
No symptoms at rest but marked limitation of ordinary physical activity (activity of daily living)
Class IV NYHA
Symptoms at rest and worse during any physical activity
Stage A ACC/ AHA
Stage A: High risk of heart failure but no structural heart disease or symptoms of heart failure
Stage b ACC
§ Stage B: Structural heart disease but no symptoms of HF
Stage C Accc
§ Stage C: Structural heart disease and symptoms of HF
Stage D ACC
§ Stage D: Refractory heart failure requiring specialized therapy
Drugs that worsen HF (Drug Information Nation)
- DPP4 inhibitors EG saxagliptin
2.Immunosuppressants TNF inhibitors {e.g., adalimumab,
etanercept) and interferons
3.Nondihydropyridine CCBs Dlltiazem and verapamil (in systolic HF)
- Antiarrhythmics Class I agents (e.g., quinidine,
flecainide) and dronedarone
Amiodarone and dofetilide are preferred in patients w ith HF
5.Thiazolidinediones risk o f edema
6.Itraconazole
7.Oncology drugs Anthracyclines (doxorubicin, daunorubicin)
8.NSAIDs All (including celecoxib)
Compensatory mechanisms in HF
- Increased sympathetic activity
- RAAS
3.CARDIAC REMODELLING
4.ENDOTHELIN - Release of Peptides
Decompensated HF
Occurs when the compensatory mechanisms fail causing acute HF unstable
Drugs recommended in HF
Amlodipine and Felodipine
Lasix will not reduce
Mortality in HF
Difference between Spironolactone and Eplerenonone
is a non-selective mineralocorticoid antagonists. it can also antagonize androgen, progesterone, is more likely to cause endocrine-related side effects like gynecomastia in men while eplerenone is a selective mineralocorticoid anatagonixt
Pleutropic benefits of Acei
- Antioxidant
- Anti-inflammatory
3.Antipoliferative - Decreases cardiac REMODELLING
- Increase Nitric oxide bioavailability
Pleutropic benefits of Statins
1.Antioxidant
2. Anti-inflammatory
3.Antipoliferative
4. Stabilisation of atherosclerotic plaques
5. Increase Nitric oxide bioavailability
Wash out period for ACEi before administration of ARNI
36hrs
The best medicine in HF with Atrial Fibrillation
DIGOXIN
DIGOXIN WILL NOT REDUCE Mortality
TRUE
MOA of Digoxin
- INCREASE force of contraction has POSITIVE INOTROPIC Effect
2.Reduces Impulses TRANSMISSION OF SINO-ATRIAL NODE
Cardiac side effects of Digoxin
Bradycardia
Heart block
Non cardiac
Vomiting, Nausea, Vision
SGLT2 ARE RECOMMENDED AS ADD ON to decrease mortality and hospitalizations, together with
ARNI or ACEi or ARBs
BB
ARA
Hydralazine and Nitrates are used for
Pts not response to ACE or despite optimal treatment with pillars
Hydralazine decreases
Afterload , direct arterial vasodilator
Nitrates decrease
Preload, venous dilator